Novartis AG - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US66987V1098
121,00 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:NOTA / Novartis AG - Depositary Receipt (Common Stock)
InstitutionCypress Capital Group
Latest Disclosed Ownership5,941 shares
Latest Disclosed Value $ 907,488
Cypress Capital Group reports 0.42% decrease in ownership of NOTA / Novartis AG - Depositary Receipt (Common Stock)

On May 15, 2026 - Cypress Capital Group filed a 13F-HR form disclosing ownership of 5,941 shares of Novartis AG - Depositary Receipt (Common Stock) (DE:NOTA) valued at $763,418 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 5,966 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of -0.42% during the quarter. The current value of the position is $718,861 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NOVARTIS SPONSORED ADR 66987V109 5,941 -25 -0.42 907 10.34 0.1021
2026-02-11 2025-12-31 13F NOVARTIS SPONSORED ADR 66987V109 5,966 210 3.65 823 11.38 0.0922
2025-11-03 2025-09-30 13F NOVARTIS SPONSORED ADR 66987V109 5,756 -20 -0.35 738 5.73 0.0883
2025-07-25 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 5,776 2,638 84.07 699 100.00 0.0870
2025-05-12 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 3,138 -20 -0.63 350 13.68 0.0458
2025-02-06 2024-12-31 13F NOVARTIS SPONSORED ADR 66987V109 3,158 -300 -8.68 307 -22.67 0.0377
2024-11-08 2024-09-30 13F NOVARTIS SPONSORED ADR 66987V109 3,458 39 1.14 398 9.37 0.0447
2024-07-25 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 3,419 -380 -10.00 364 -1.09 0.0436
2024-05-08 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 3,799 -105 -2.69 367 -6.85 0.0440
2024-01-24 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 3,904 -231 -5.59 394 -6.41 0.0513
2023-11-02 2023-09-30 13F NOVARTIS SPONSORED ADR 66987V109 4,135 -152 -3.55 421 -2.55 0.0608
2023-07-26 2023-06-30 13F NOVARTIS SPONSORED ADR 66987V109 4,287 -71 -1.63 433 8.00 0.0626
2023-05-04 2023-03-31 13F NOVARTIS SPONSORED ADR 66987V109 4,358 -10 -0.23 401 1.01 0.0615
2023-02-14 2022-12-31 13F NOVARTIS SPONSORED ADR 66987V109 4,368 -13 -0.30 396 18.92 0.0598
2022-11-04 2022-09-30 13F NOVARTIS A G SPONSORED ADR 66987V109 4,381 -55 -1.24 333 -11.20 0.0555
2022-07-26 2022-06-30 13F NOVARTIS A G SPONSORED ADR 66987V109 4,436 -30 -0.67 375 -4.34 0.0571
2022-05-16 2022-03-31 13F NOVARTIS A G SPONSORED ADR 66987V109 4,466 -676 -13.15 392 -12.89 0.0483
2022-02-15 2021-12-31 13F NOVARTIS A G SPONSORED ADR 66987V109 5,142 66 1.30 450 8.43 0.0563
2021-10-12 2021-09-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 5,076 159 3.23 415 -7.37 0.0564
2021-07-13 2021-06-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,917 0 0.00 448 6.67 0.0607
2021-04-14 2021-03-31 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,917 -5 -0.10 420 -9.48 0.0596
2021-01-12 2020-12-31 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,922 -377 -7.11 464 0.65 0.0699
2020-10-08 2020-09-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 5,299 601 12.79 461 12.17 0.0768
2020-07-10 2020-06-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,698 310 7.06 411 13.54 0.0753
2020-04-08 2020-03-31 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,388 156 3.69 362 -9.73 0.0835
2020-01-10 2019-12-31 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,232 -10 -0.24 401 8.67 0.0714
2019-10-10 2019-09-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,242 114 2.76 369 -2.12 0.0711
2019-08-15 2019-06-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 4,128 400 10.73 377 5.31 0.0744
2019-05-14 2019-03-31 13F NOVARTIS A G FOREIGN STOCK 66987V109 3,728 383 11.45 358 24.74 0.0733
2019-02-19 2018-12-31 13F NOVARTIS A G FOREIGN STOCK 66987V109 3,345 310 10.21 287 9.96 0.0658
2018-11-15 2018-09-30 13F NOVARTIS A G FOREIGN STOCK 66987V109 3,035 3,035 261 0.0495
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.